FDA Issues 5-Year Debarment Order Against Francis Esteban Matos for Drug Importation Violations

What this means for your practice

This FDA debarment order underscores the agency's vigilance in maintaining the integrity of the U.S. drug supply chain. For telehealth brands, medspas, dental practices, chiropractic offices, and other healthcare businesses, this serves as a critical reminder of the stringent regulations surrounding drug procurement and importation. While many practices may not directly import drugs, they rely on a complex supply chain. The FDA's consistent enforcement actions, such as debarment, highlight the potential risks associated with engaging, directly or indirectly, with individuals or entities involved in unlawful importation. Practices must exercise robust due diligence when selecting suppliers, distributors, and partners to ensure all procured drugs, medical devices, and related substances comply with federal law. Failure to do so could lead to the introduction of unapproved, misbranded, or adulterated products into patient care, posing significant patient safety risks and severe regulatory and legal consequences for the practice. Compliance with federal importation laws, even if managed by a third party, remains the responsibility of all entities within the healthcare ecosystem.

Rockville, MD – The Food and Drug Administration (FDA) has announced a final order to debar Francis Esteban Matos for a period of five years from importing or offering for import any drug into the United States. This enforcement action, effective July 24, 2026, stems from a finding that Mr. Matos was convicted of a felony under Federal law, specifically related to conduct involving the importation of a drug or controlled substance.

Regulatory Background and Authority

Under section 306(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 335a(b)(1)(D)), the FDA is authorized to debar an individual from importing or offering for import any drug into the United States if the agency finds that the individual has been convicted of a felony under Federal law, and the factual basis for that conviction relates to the importation of a drug or controlled substance. This statutory provision is a crucial tool for the FDA to protect the public health by preventing individuals with a history of illicit drug importation from participating in the regulated supply chain.

Details of the Debarment Action

Mr. Matos's debarment follows a conviction for a felony offense under Federal law, the specifics of which relate directly to the unlawful importation of drugs or controlled substances. The FDA provided Mr. Matos with official notice of the proposed debarment, which included an opportunity to request a hearing. Such a hearing would have allowed Mr. Matos to present arguments or evidence to demonstrate why he should not be debarred. However, as of May 18, 2026, more than 30 days after receiving the notice, Mr. Matos failed to respond or request a hearing. The FDA determined that this failure constituted a waiver of his right to a hearing concerning the matter, leading to the issuance of the final debarment order.

Impact of Debarment

The debarment order prohibits Francis Esteban Matos from engaging in any activities related to importing or offering for import any drugs into the United States for a period of five years. This means he is legally barred from participating in any part of the legitimate drug importation process, thereby mitigating potential risks to the U.S. drug supply posed by individuals convicted of related felonies.

Provisions for Termination of Debarment

While the debarment is for a period of five years, the FD&C Act also provides a mechanism for individuals to apply for early termination of debarment. Section 306(d)(1) of the FD&C Act allows for such applications. Mr. Matos may submit an application for termination of debarment at any time. Applications can be submitted electronically via the Federal eRulemaking Portal at www.regulations.gov or through written/paper submissions mailed to the FDA Dockets Management Staff. Applicants are advised to include Docket No. FDA-2026-N-1199 with their submissions.

It is important for any applicant to be aware of the FDA's policies regarding confidential information. While electronic submissions will be posted publicly, applicants have the option for written/paper submissions to redact confidential information, provided specific instructions for submission of confidential materials are followed.

Broader Implications for the Healthcare Industry

This final debarment order reinforces the FDA's commitment to rigorous enforcement against those who compromise the integrity of the drug supply chain. Healthcare providers, pharmacies, and any entity involved in the distribution or dispensing of pharmaceutical products must understand the gravity of these regulations. The FDA's ability to debar individuals is a critical measure to protect public health from unsafe, ineffective, or unapproved drugs that could enter the country through illicit means. Due diligence in vetting suppliers and ensuring compliance with all federal drug importation laws remains paramount for all stakeholders in the healthcare sector.

Key Facts

| Detail | Value | |---|---| | Debarred Individual | Francis Esteban Matos | | Debarment Period | 5 years | | Reason for Debarment | Conviction of a felony under Federal law related to the importation of a drug or controlled substance | | Applicable Date of Order | July 24, 2026 | | Agency | Food and Drug Administration (FDA) | | Relevant Statute | Section 306(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 335a(b)(1)(D)) |

Frequently Asked Questions

What does it mean to be 'debarred' by the FDA?

Debarment means an individual is prohibited for a specified period from importing or offering for import any drug into the United States, as determined by the FDA under the Federal Food, Drug, and Cosmetic Act.

Why was Francis Esteban Matos debarred?

Mr. Matos was debarred because he was convicted of a felony under Federal law, and the conduct supporting this conviction related to the importation into the United States of a drug or controlled substance.

How long is the debarment for Francis Esteban Matos?

The debarment order is for a period of 5 years.

What is the effective date of this debarment order?

This order is applicable as of July 24, 2026.

Can a debarred individual apply to have their debarment terminated early?

Yes, an individual may submit an application for termination of debarment at any time under section 306(d)(1) of the FD&C Act.

Source: FDA — Notice: Francis Esteban Matos: Final Debarment Order · 2026-07-24